Last ¥7,410 JPY
Change Today +40.00 / 0.54%
Volume 45.8K
4581 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
As of 1:00 AM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

taisho pharmaceutical holdin (4581) Snapshot

Open
¥7,380
Previous Close
¥7,370
Day High
¥7,420
Day Low
¥7,360
52 Week High
04/1/14 - ¥8,390
52 Week Low
10/17/14 - ¥6,780
Market Cap
667.9B
Average Volume 10 Days
82.9K
EPS TTM
¥354.84
Shares Outstanding
90.1M
EX-Date
03/27/15
P/E TM
20.9x
Dividend
¥110.00
Dividend Yield
1.48%
Current Stock Chart for TAISHO PHARMACEUTICAL HOLDIN (4581)

Related News

No related news articles were found.

taisho pharmaceutical holdin (4581) Related Businessweek News

No Related Businessweek News Found

taisho pharmaceutical holdin (4581) Details

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, and sells over-the-counter (OTC) drugs and prescription pharmaceuticals in Japan and internationally. The company operates in two segments, Self-Medication Operation Group and Prescription Drug Operation Group. The Self-Medication Operation Group segment manufactures and sells OTC drugs, quasi drugs, and food products, as well as general, medical, and hygiene supplies. Its principal products include the Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatment products, as well as mouthwash, hand wash, and face masks; the RiUP series of hair re-growth treatment products; Livita series of food products for specialized health use, etc.; the Taisho Kampo Ichoyaku series of gastrointestinal treatment products; and the Colac series of laxative products. This segment also engages in real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment manufactures and sells ethical drugs. Its products comprise Clarith, a macrolide antibiotic; ZOSYN, an antibiotic of penicillin with ß-lactamase inhibitor; Palux, a peripheral vasodilator; osteoporosis agents, such as vitamin D3 agent and bisphosphonate antiresorptive agent; Lusefi that is used for type 2 diabetes treatment; Lorcam, a nonsteroidal anti-inflammatory drug; and other inflammation/immune-related products. This segment is also developing various topical and oral products for osteoarthritis, asthma, type 2 diabetes, intermittent claudication, central disorders of hypersomnolence, and depression. The company also offers raw materials for medicines and drugs; employee welfare and benefit services; and supplies health foods and skin care products Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.

6,381 Employees
Last Reported Date: 06/27/14
Founded in 1912

taisho pharmaceutical holdin (4581) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

taisho pharmaceutical holdin (4581) Key Developments

Taisho Pharmaceutical Holdings Co., Ltd., Q2 2015 Earnings Call, Oct 31, 2014

Taisho Pharmaceutical Holdings Co., Ltd., Q2 2015 Earnings Call, Oct 31, 2014

Taisho Pharmaceutical Holdings Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year Ending March 31, 2015; Declares Dividend for the Second Quarter Ended September 30, 2014, Payable on December 4, 2014; Provides Dividend Guidance for the Fiscal 2014

Taisho Pharmaceutical Holdings Co., Ltd. reported consolidated earnings results for the six months ended September 30, 2014. For the quarter, the company reported net sales of ¥141,805 million compared to ¥144,563 million a year ago. Operating income was ¥16,231 million compared to ¥21,509 million a year ago. Ordinary income was ¥19,587 million compared to ¥25,575 million a year ago. Income before income taxes and minority interests was ¥20,256 million compared to ¥25,665 million a year ago. Net income was ¥12,593 million or ¥155.27 per basic share compared to ¥16,516 million or ¥203.68 per basic share a year ago. Diluted net income per share was ¥203.63 against ¥156.86 a year ago. Net cash provided by operating activities was ¥15,037 million against ¥30,601 million a year ago. Payments for purchases of tangible fixed assets were ¥3,208 million against ¥5,541 million a year ago. Payments for purchases of intangible fixed assets were ¥183 million against ¥175 million a year ago. The company provided earnings guidance for the full year ending March 31, 2015. For the period, the company expects net sales of ¥293,000 million, operating income of ¥29,000 million, ordinary income of ¥37,000 million, and net income of ¥24,000 million or ¥296.05 per share. The company declared second quarter dividend for the period ended September 30, 2014 at the rate of JPY 50 per share. Scheduled date of dividend payment is December 4, 2014. The company provided dividend guidance for the fiscal year 2014. For the year, the company expects to pay fiscal year-end dividend of JPY 60 per share.

Taisho Pharmaceutical Holdings Co., Ltd. to Report Q2, 2015 Results on Oct 31, 2014

Taisho Pharmaceutical Holdings Co., Ltd. announced that they will report Q2, 2015 results on Oct 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4581:JP ¥7,410.00 JPY +40.00

4581 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Britvic PLC 673.00 GBp -4.00
Coca-Cola Amatil Ltd A$9.16 AUD -0.02
Dr Pepper Snapple Group Inc $73.20 USD -0.28
National Beverage Corp $23.30 USD +0.03
Relentless Resources Ltd C$0.28 CAD 0.00
View Industry Companies
 

Industry Analysis

4581

Industry Average

Valuation 4581 Industry Range
Price/Earnings 4.9x
Price/Sales 0.5x
Price/Book 0.2x
Price/Cash Flow 18.1x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAISHO PHARMACEUTICAL HOLDIN, please visit www.taisho-holdings.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.